Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA cleared an IND application for a gene therapy being researched at Massachusetts General Hospital.1 source
- Solid Biosciences gets FDA approval for gene therapy trial.
Keep exploring
The entities involved
- FDA
-
Massachusetts General Hospital
teaching hospital in Boston, Massachusetts, United States
Related events
- FDA placed a clinical hold on a gene therapy involving Hunter.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- prnewswire.com
- Unknown outlet